Physician profile
Janice E Ma
NPI 1306330410
$6,397.11
in general payments reported to CMS, 2019-2025
25 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $331 · 2023: $2,078 · 2024: $2,016 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,968 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,967.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.28 | 2022-2025 | |
| Incyte Corporation | $1,037.02 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $875.77 | 2023-2024 | Vtama |
| Genzyme Corporation | $782.67 | 2023-2025 | |
| Galderma Laboratories, L.P. | $431.50 | 2022-2025 | Aklief, Epsolay, Nemluvio |
| Strata Skin Sciences, INC. | $252.37 | 2023-2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $246.76 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $222.66 | 2023-2025 | |
| Ucb, INC. | $191.43 | 2025 | Bimzelx |
| Leo Pharma INC. | $177.58 | 2025 | Adbry, Anzupgo |
| Pfizer INC. | $166.92 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $146.57 | 2024-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.67 | 2024-2025 | Jublia, Siliq, Duobrii |
| Lilly USA, LLC | $96.88 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $87.11 | 2024-2025 | Tremfya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $80.36 | 2022-2024 | |
| Amgen INC. | $69.55 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $69.20 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $66.03 | 2023-2025 | Sotyktu |
| Almirall LLC | $54.96 | 2024-2025 | Seysara, Klisyri |
| Botanix Sb INC | $41.14 | 2025 | Sofdra |
| Vertex Pharmaceuticals Incorporated | $32.93 | 2025 | |
| Organon LLC | $29.09 | 2025 | Vtama |
| Allergan, INC. | $24.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.